Use of BPC-157, the Unapproved 'Wolverine' Peptide, Is Climbing Fast in U.S. Medical Records

BPC-157 is not an approved drug, and most physicians have never prescribed it. It is also turning up in a growing number of U.S. patient charts. A preliminary analysis of more than 15 million medical records, run by the analytics firm nference and reported by Reuters on September 16, 2026, found that documented use of BPC-157 has climbed sharply since 2020.

nference released the work ahead of peer review, so the numbers are an early estimate rather than a settled finding. Even so, it is one of the first attempts to measure how far a gray-market peptide has spread, and it arrives just as federal regulators weigh whether pharmacies should be allowed to compound it.

What the analysis found

nference identified 1,039 patients whose doctors had written BPC-157 into their clinical notes, with new users rising about 33-fold from 2020 to 2026. Because the tally depends on a clinician bothering to record a drug the patient bought on their own, the real figure is almost certainly far higher. The firm's lead scientist, Venky Soundararajan, put it plainly: very few doctors are even asking patients whether they take BPC-157.

Who is using it, and why

The user base shifted as the count grew. New users became more male, from about 57 percent in 2020 to 70 percent in 2026, and younger, with the average age falling from about 55 to 49. Where a reason was recorded (644 patients), it was usually a sports injury, chronic pain, or a gastrointestinal problem, matching the healing and recovery claims made for the peptide online. A treatment response was noted for only about a third of patients, and chart data like this cannot show whether the peptide actually works.

What the 'Wolverine stack' is

BPC-157 is a synthetic peptide, frequently paired with TB-500 in a combination users call the 'Wolverine stack' after the comic-book character's fast healing. Sellers promote it for injury recovery, pain, and athletic performance, none of which is backed by large human trials. Health Secretary Robert F. Kennedy Jr. has publicly pushed for broader access, which has raised its profile. Products sold as research chemicals, often labeled not for human use, are not held to pharmaceutical quality standards, and the FDA does not verify their contents or purity.

The safety signal

The FDA has begun to log harm. Its Adverse Event Reporting System has recorded 10 reports of problems in people using BPC-157 since 2021, all of them serious, and eight were filed in 2026 as use accelerated. Such reports do not prove the peptide caused the harm, but a run of serious ones is exactly what safety monitors watch for.

How this connects to the FDA compounding vote

The findings also land months after a contentious regulatory moment. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 and five other peptides for the Section 503A bulks list, the set of substances licensed pharmacies may compound. FDA career scientists had urged the panel to reject all seven peptides under review, citing thin human evidence, so the committee overrode its own agency's reviewers.

The vote is only a recommendation. The FDA can accept or reject it, and any addition to the list would still require formal rulemaking, so nothing about what pharmacies may legally compound has changed. For now the July vote points to a possible future pathway, not an approval.

What this means for telehealth patients

If you run into BPC-157 through a telehealth clinic, a wellness provider, or a social-media seller, the short version is that demand is outrunning the evidence. An unapproved peptide with a growing count of serious adverse-event reports, sold largely outside the regulated supply chain, carries risks a marketing page will not spell out. This is general information for a telehealth audience, not medical advice: anyone considering or already using a peptide should tell their own licensed clinician and rely on primary FDA documents rather than seller claims.

Limits and what is not settled

The analysis has not been peer reviewed, and its counts rest on clinicians recording a drug patients bought on their own, so they understate real use. Observational data cannot establish safety or effectiveness, and adverse-event reports do not prove causation. The July FDA vote remains a recommendation with no final rule behind it. None of the figures here is an endorsement of the peptide.